Business
Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
- Company completed recent transaction to expand oncology pipeline with in-licensing of DNase based platform comprising multiple therapeutic modalities- DNase
About this update from Xenetic Biosciences, Inc.
[{"type":"text","content":"- Company completed recent transaction to expand oncology pipeline with in-licensing of DNase based platform comprising multiple therapeutic modalities- DNase based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indications- Focusing resources on advancing DNase based oncology platform in locally advanced or metastatic solid tumors towards Phase 1 clinical development- Ended the quarter with $16.2 million of cash to fund operations and drive pipeline forwardFRAMINGHAM, MA / ACCESSWIRE / May 12, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (\"Xenetic\" or the \"Company\"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today reported its financial results for the first quarter of 2022 and provided a business update.\"Our strategic focus throughout the first quarter was working towards the completion of our exclusive license agreement with CLS Therapeutics (\"CLS\") to develop its interventional DNase based oncology platform. This platform was extremely attractive to us as we realized that adding the licensed programs could expand and enhance our oncology pipeline, provide an accelerated path to the clinic, create the potential for value-driving clinical and regulatory milestones, and position us as an emerging clinical-stage company,\" commented, Jeffrey Eisenberg, Chief Executive Officer of Xenetic. \"Our team, along with advisors and preeminent key opinion leaders in this space, will make it a priority to advance the systemic DNase program into the clinic as an adjunctive therapy for locally advanced or metastatic cancers, as quickly and efficiently as possible.\"DNase Oncology Platform: Targeting Neutrophil Extracellular Traps (\"NETs\") to improve cancer therapies with a focus on advancing systemic DNase program into the clinic as an adjunctive therapy for locally advanced or metastatic cancers.The Company's interventional DNase based oncology platform is aimed at improving outcomes of existing treatments, including immunotherapies. The exclusive license to CLS' intellectual property for uses of DNases in cancer include systemic co-administration of DNases along with standard therapies, including chemotherapy, radiation and checkpoint inhibitors, or along with conventional ...